Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2022 08:00 ET | Source: MediWound Ltd.

MediWound to Report Third Quarter 2022 Financial Results

YAVNE, Israel, Nov. 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
October 25, 2022 07:00 ET | Source: MediWound Ltd.

MediWound Announces Formation of Strategic Advisory Board

YAVNE, Israel, Oct. 25, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
October 18, 2022 07:00 ET | Source: MediWound Ltd.

MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022

YAVNE, Israel, Oct. 18, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
October 07, 2022 06:00 ET | Source: MediWound Ltd.

MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings

YAVNE, Israel, Oct. 07, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
September 22, 2022 08:02 ET | Source: MediWound Ltd.

MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 Million

YAVNE, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for...
September 20, 2022 07:00 ET | Source: MediWound Ltd.

EMA Accepts MediWound’s Application for Extended Indication for NexoBrid to Treat Pediatric Patients with Severe Thermal Burns

YAVNE, Israel, Sept. 20, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for...
September 12, 2022 08:00 ET | Source: MediWound Ltd.

MediWound’s NexoBrid® Highlighted in 45 Posters and Presentations at the 19th European Burns Association Congress

YAVNE, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions...
August 09, 2022 07:30 ET | Source: MediWound Ltd.

MediWound Reports Second Quarter 2022 Financial Results and Provides Company Updates

Positive Results in Two Phase 2 Trials of EscharEx FDA Assigned PDUFA Target Date of January 1, 2023 for NexoBrid BLA Enhanced the Board and Leadership Team Conference Call Begins Today at 8:30 AM...
August 08, 2022 16:05 ET | Source: MediWound Ltd.

MediWound Enhances Its Board and Executive Leadership Team

Mr. Nachum Shamir appointed as Chairman of the Board Dr. Robert Snyder appointed as Chief Medical Officer YAVNE, Israel, Aug. 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the...
August 03, 2022 07:30 ET | Source: MediWound Ltd.

MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns

YAVNE, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right